Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YH01 intravesical instillation in BCG-unresponsive or BCG-failed intermediate/high-risk NMIBC (Phase II, multicenter, China)
CTR20243936Phase 2Active
- Sponsor
- InmFuture
- Start
- Dec 2024
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of YH01 in bladder cancer, Bladder cancer in situ (CIS), sponsored by InmFuture. Started Dec 2024; status: active.
02
Drugs
YH01
03
Conditions
bladder cancerBladder cancer in situ (CIS)
Beyond the preview
Go deeper on CTR20243936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243936.